Matthew P. Goetz
A5008665323- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Pharmacogenetics and Drug Metabolism
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Inflammatory mediators and NSAID effects
- Cancer-related Molecular Pathways
- Cancer Cells and Metastasis
- PARP inhibition in cancer therapy
- Lung Cancer Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Cancer-related molecular mechanisms research
- Esophageal Cancer Research and Treatment
- DNA Repair Mechanisms
- PI3K/AKT/mTOR signaling in cancer
- Breast Lesions and Carcinomas
- Nutrition, Genetics, and Disease
- Bioinformatics and Genomic Networks
- Colorectal Cancer Treatments and Studies
Mayo Clinic
2016-2025
WinnMed
2016-2025
Mayo Clinic in Arizona
2016-2025
Mayo Clinic in Florida
2010-2025
Jacksonville College
2016-2024
Fox Chase Cancer Center
2015-2023
Washington University in St. Louis
2023
International Breast Cancer Study Group
2022
Alliance for Clinical Trials in Oncology
2013-2022
National Institutes of Health
2022
The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of in absence low; however, there uncertainty about for most patients, who have midrange score.We performed prospective trial involving 10,273 women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative cancer. Of 9719 eligible patients follow-up information, 6711 (69%) had 11 to 25 were randomly assigned receive...
Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group neoplastic lesions ducts. The goal for management DCIS is to prevent development invasive cancer. This manuscript focuses on NCCN Guidelines Panel recommendations workup, primary treatment, risk reduction strategies, and surveillance specific DCIS.
Several new systemic therapy options have become available for patients with metastatic breast cancer, which led to improvements in survival. In addition patient and clinical factors, the treatment selection primarily depends on tumor biology (hormone-receptor status HER2-status). The NCCN Guidelines specific workup of recurrent/stage IV cancer are discussed this article.
Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy in combination with fulvestrant women hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer previously treated endocrine therapy. Methods MONARCH 3 is double-blind, randomized phase III study of abemaciclib or placebo plus nonsteroidal aromatase inhibitor 493 postmenopausal HR-positive, HER2-negative who had no prior systemic therapy the...
Polymorphisms in tamoxifen metabolizing genes affect the plasma concentration of metabolites, but their effect on clinical outcome is unknown.We determined cytochrome P450 (CYP)2D6 (*4 and *6) CYP3A5 (*3) genotype from paraffin-embedded tumor samples buccal cells (living patients) tamoxifen-treated women enrolled onto a North Central Cancer Treatment Group adjuvant breast cancer trial. The relationship between disease was using log-rank test Cox proportional hazards modeling.Paraffin blocks...
The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines Breast Cancer include recommendations clinical management of carcinoma in situ, cancer, Paget disease, phyllodes tumor, inflammatory during pregnancy. content featured this issue focuses on the overall ductal situ workup locoregional early stage cancer. For full version Cancer, visit NCCN.org .
Purpose Few options are available for pain relief in patients with bone metastases who fail standard treatments. We sought to determine the benefit of radiofrequency ablation (RFA) providing refractory secondary involving bone. Patients and Methods Thirty-one US 12 European painful osteolytic were treated image-guided RFA using a multitip needle. Treated had ≥ 4/10 either failed or poor candidates treatments such as radiation opioid analgesics. Using Brief Pain Inventory–Short Form, worst...
In the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen Exemestane (TEXT), 5-year rates recurrence breast cancer were significantly lower among premenopausal women who received aromatase inhibitor exemestane plus ovarian suppression than those tamoxifen suppression. The addition to did not result in with alone. Here, we report updated results from two trials.
Abstract At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and objective response rate (ORR) with tolerable safety profile as initial treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC). is randomized, phase III, double-blind study of abemaciclib/placebo (150 mg twice daily, continuous) AI (1 anastrozole or 2.5...
These NCCN Guidelines Insights highlight the important updates/changes to surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in 1.2017 version of Breast Cancer. This report summarizes these updates discusses rationale behind them. Updates on new drug approvals, not available at press time, can be found most recent guidelines NCCN.org.
The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on 21-gene assay to determine the risk recurrence. Whether level clinical recurrence adds prognostic information is not known.
Recent changes have occurred in the presurgical planning for breast cancer, including introduction of preoperative magnetic resonance imaging (MRI). We sought to analyze trends mastectomy rates and relationship MRI surgical year at Mayo Clinic, Rochester, MN.We identified 5,405 patients who underwent surgery between 1997 2006. Patients undergoing were from a prospective database. Trends rate association with type analyzed. Multiple logistic regression was used assess effect on type, while...
To provide recommendations on the appropriate use of breast tumor biomarker assay results to guide decisions systemic therapy for metastatic cancer.A literature search and prospectively defined study selection identified systematic reviews, meta-analyses, randomized controlled trials (RCTs), prospective-retrospective studies, prospective comparative observational studies published from 2006 through September 2014.The revealed 17 articles that met criteria further review: 11 reporting...
We determined the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLT) of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when infused on days 1, 8, 15 a 28-day cycle in advanced solid tumor patients. also characterized pharmacokinetics 17-AAG, its effect chaperone client proteins, whether cytochrome P450 (CYP) 3A5 NAD(P)H:quinone oxidoreductase 1 (NQO1) polymorphisms affected 17-AAG disposition or toxicity.An accelerated titration design was used. Biomarkers were measured...
Abstract Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) assessed the antiproliferative activity of CDK4/6 inhibitor palbociclib primary cancer as a prelude to adjuvant studies. Experimental Design: Eligible patients with clinical stage II/III ER+/HER2− received anastrozole 1 mg daily for 4 weeks (cycle 0; goserelin if premenopausal), followed by adding (125 on days...
Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free (DRFS) hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of prespecified primary outcome analysis an additional analysis.This global, phase III,...
Breast cancer is the most common malignancy in women United States and second only to lung as a cause of death. The overall management breast includes treatment local disease with surgery, radiation therapy, or both, systemic cytotoxic chemotherapy, endocrine biologic combinations these. This article outlines NCCN Guidelines specific that locoregional (restricted one region body), discusses clinical stage I, II, IIIA (T3N1M0) tumors. For on adjuvant therapy after II for other stages cancer,...
BackgroundPrevious studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate relationship RCB with long-term prognosis across different phenotypic subtypes breast cancer, assess generalisability broad range practice settings.MethodsIn this analysis, 12 institutes and trials Europe USA were identified by personal communications...
Tamoxifen is biotransformed by CYP2D6 to 4‐hydroxytamoxifen and 4‐hydroxy N‐desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients certain genetic polymorphisms patients who receive strong inhibitors exhibit lower endoxifen concentrations a higher risk of disease recurrence in some studies adjuvant therapy early breast cancer. We summarize evidence from literature provide therapeutic recommendations for based on genotype.
Abstract BACKGROUND: This study sought to describe the results of a single‐arm multicenter clinical trial using image‐guided percutaneous cryoablation for palliation painful metastatic tumors involving bone. METHODS: Over 44‐month period, 61 adult patients with 1 or 2 bone metastases score 4 more on scale 0 10 (≥4/10) worst pain in 24‐hour period who had failed refused conventional treatment were treated cryoablation. Patient and quality life was measured Brief Pain Inventory prior...
The NCCN Guidelines for Breast Cancer include up-to-date guidelines clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory male and cancer during pregnancy. These are developed by a multidisciplinary panel representatives from Member Institutions cancer–focused expertise the fields medical oncology, surgical radiation pathology, reconstructive surgery, patient advocacy. Insights focus on most recent updates to...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management breast cancer. treatment landscape metastatic cancer is evolving constantly. therapeutic strategy takes into consideration tumor biology, biomarkers, and other clinical factors. Due to the growing number options, if one option fails, there usually another line therapy available, providing meaningful improvements survival. This Insights report focuses on recent updates...
We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)- amplified xenografts in mice by inhibition HER2 pathway with lapatinib and trastuzumab to block all homo- heterodimer signaling as well blockade estrogen (ER) when expressed. In this clinical trial, we sought translate these findings patients using targeted therapy without chemotherapy.Women stages II III HER2-positive breast cancers were eligible. They received once per week (4 mg/kg loading, then...